Transthyretin Predicts Cardiovascular Outcome In Hemodialysis Patients With Diabetes Mellitus Type 2

BMI and albumin are commonly accepted parameters to recognize wasting in dialysis patients and are powerful predictors of morbidity and mortality. However, both parameters reveal limitations and may not cover the entire range of patients with wasting. The visceral protein transthyretin (TTR) may be...

Full description

Bibliographic Details
Main Authors: Andrea Henze, Katharina Espe, Christoph Wanner, Vera Krane, Jens Raila, Berthold Hocher, Florian J. Schweigert, Christiane Drechsler
Format: Article
Language:English
Published: The Korean Society of Nephrology 2012-06-01
Series:Kidney Research and Clinical Practice
Online Access:http://www.sciencedirect.com/science/article/pii/S2211913212004330
id doaj-31b1b7d52117425b93882de0bfc4bb17
record_format Article
spelling doaj-31b1b7d52117425b93882de0bfc4bb172020-11-25T02:47:15ZengThe Korean Society of NephrologyKidney Research and Clinical Practice2211-91322012-06-01312A3510.1016/j.krcp.2012.04.400Transthyretin Predicts Cardiovascular Outcome In Hemodialysis Patients With Diabetes Mellitus Type 2Andrea HenzeKatharina EspeChristoph WannerVera KraneJens RailaBerthold HocherFlorian J. SchweigertChristiane DrechslerBMI and albumin are commonly accepted parameters to recognize wasting in dialysis patients and are powerful predictors of morbidity and mortality. However, both parameters reveal limitations and may not cover the entire range of patients with wasting. The visceral protein transthyretin (TTR) may be helpful in overcoming the diagnostic and prognostic gap. Therefore, the aim of this study was to assess the association of TTR with morbidity and mortality in hemodialysis patients. The TTR concentration was determined in baseline plasma samples of 1177 hemodialysis patients with diabetes mellitus type 2. Cox regression analyses were used to determine hazard ratios for the risk of cardiovascular events (CVE) and mortality according to quartiles of TTR plasma concentration for the total study cohort and the subgroups BMI ≥23kg/m², albumin concentration ≥3.8g/dL and a combination of both. A low TTR concentration was associated with an increased risk for CVE for the total study cohort (HR 1.65; 95% CI 1.27-2.14), patients with BMI ≥23kg/m² (HR 1.70; 95% CI 1.22–2.37), albumin ≥3.8g/dL (HR 1.68; 95% CI 1.17–2.42) and the combination of both (HR 1.69; 95% CI 1.13-2.53). Additionally, a low TTR concentration predicted all-cause mortality for the total study cohort (HR 1.79; 95% CI 1.43–2.24) and patients with BMI ≥23kg/m² (HR 1.46; 95% CI 1.09–1.95). In conclusion, the present study demonstrated that TTR is a useful predictor for cardiovascular outcome and mortality in hemodialysis patients. TTR was particularly useful in patients who were not identified to be at risk by BMI or albumin status.http://www.sciencedirect.com/science/article/pii/S2211913212004330
collection DOAJ
language English
format Article
sources DOAJ
author Andrea Henze
Katharina Espe
Christoph Wanner
Vera Krane
Jens Raila
Berthold Hocher
Florian J. Schweigert
Christiane Drechsler
spellingShingle Andrea Henze
Katharina Espe
Christoph Wanner
Vera Krane
Jens Raila
Berthold Hocher
Florian J. Schweigert
Christiane Drechsler
Transthyretin Predicts Cardiovascular Outcome In Hemodialysis Patients With Diabetes Mellitus Type 2
Kidney Research and Clinical Practice
author_facet Andrea Henze
Katharina Espe
Christoph Wanner
Vera Krane
Jens Raila
Berthold Hocher
Florian J. Schweigert
Christiane Drechsler
author_sort Andrea Henze
title Transthyretin Predicts Cardiovascular Outcome In Hemodialysis Patients With Diabetes Mellitus Type 2
title_short Transthyretin Predicts Cardiovascular Outcome In Hemodialysis Patients With Diabetes Mellitus Type 2
title_full Transthyretin Predicts Cardiovascular Outcome In Hemodialysis Patients With Diabetes Mellitus Type 2
title_fullStr Transthyretin Predicts Cardiovascular Outcome In Hemodialysis Patients With Diabetes Mellitus Type 2
title_full_unstemmed Transthyretin Predicts Cardiovascular Outcome In Hemodialysis Patients With Diabetes Mellitus Type 2
title_sort transthyretin predicts cardiovascular outcome in hemodialysis patients with diabetes mellitus type 2
publisher The Korean Society of Nephrology
series Kidney Research and Clinical Practice
issn 2211-9132
publishDate 2012-06-01
description BMI and albumin are commonly accepted parameters to recognize wasting in dialysis patients and are powerful predictors of morbidity and mortality. However, both parameters reveal limitations and may not cover the entire range of patients with wasting. The visceral protein transthyretin (TTR) may be helpful in overcoming the diagnostic and prognostic gap. Therefore, the aim of this study was to assess the association of TTR with morbidity and mortality in hemodialysis patients. The TTR concentration was determined in baseline plasma samples of 1177 hemodialysis patients with diabetes mellitus type 2. Cox regression analyses were used to determine hazard ratios for the risk of cardiovascular events (CVE) and mortality according to quartiles of TTR plasma concentration for the total study cohort and the subgroups BMI ≥23kg/m², albumin concentration ≥3.8g/dL and a combination of both. A low TTR concentration was associated with an increased risk for CVE for the total study cohort (HR 1.65; 95% CI 1.27-2.14), patients with BMI ≥23kg/m² (HR 1.70; 95% CI 1.22–2.37), albumin ≥3.8g/dL (HR 1.68; 95% CI 1.17–2.42) and the combination of both (HR 1.69; 95% CI 1.13-2.53). Additionally, a low TTR concentration predicted all-cause mortality for the total study cohort (HR 1.79; 95% CI 1.43–2.24) and patients with BMI ≥23kg/m² (HR 1.46; 95% CI 1.09–1.95). In conclusion, the present study demonstrated that TTR is a useful predictor for cardiovascular outcome and mortality in hemodialysis patients. TTR was particularly useful in patients who were not identified to be at risk by BMI or albumin status.
url http://www.sciencedirect.com/science/article/pii/S2211913212004330
work_keys_str_mv AT andreahenze transthyretinpredictscardiovascularoutcomeinhemodialysispatientswithdiabetesmellitustype2
AT katharinaespe transthyretinpredictscardiovascularoutcomeinhemodialysispatientswithdiabetesmellitustype2
AT christophwanner transthyretinpredictscardiovascularoutcomeinhemodialysispatientswithdiabetesmellitustype2
AT verakrane transthyretinpredictscardiovascularoutcomeinhemodialysispatientswithdiabetesmellitustype2
AT jensraila transthyretinpredictscardiovascularoutcomeinhemodialysispatientswithdiabetesmellitustype2
AT bertholdhocher transthyretinpredictscardiovascularoutcomeinhemodialysispatientswithdiabetesmellitustype2
AT florianjschweigert transthyretinpredictscardiovascularoutcomeinhemodialysispatientswithdiabetesmellitustype2
AT christianedrechsler transthyretinpredictscardiovascularoutcomeinhemodialysispatientswithdiabetesmellitustype2
_version_ 1724753912672550912